<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">771248</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2021.771248</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A Highly Sensitive GFP Activation Assay for Detection of DNA Cleavage in Cells</article-title>
<alt-title alt-title-type="left-running-head">Hu et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Detection of DNA Cleavage</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Ziying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1108023/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Chengdong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1096476/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Daqi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1511027/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Siqi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1511105/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ong</surname>
<given-names>Sang-Ging</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Yongming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1031191/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zheng</surname>
<given-names>Wei V.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/457926/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Centre for Assisted Reproduction, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Department of Pharmacology, University of Illinois College of Medicine, <addr-line>Chicago</addr-line>, <addr-line>IL</addr-line>, <country>United States</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>Division of Cardiology, Department of Medicine, University of Illinois College of Medicine, <addr-line>Chicago</addr-line>, <addr-line>IL</addr-line>, <country>United States</country>
</aff>
<aff id="aff5">
<label>
<sup>5</sup>
</label>Shanghai Engineering Research Center of Industrial Microorganisms, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff6">
<label>
<sup>6</sup>
</label>Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, <addr-line>Shenzhen</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1013063/overview">Puping Liang</ext-link>, Sun Yat-sen University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1388316/overview">Yujing Li</ext-link>, Indiana University-Purdue University Indianapolis, United&#x20;States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1496776/overview">Xin Han</ext-link>, Nanjing University of Chinese Medicine, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Yongming Wang, <email>ymw@fudan.edu.cn</email>; Wei V. Zheng, <email>zhengw2013@yeah.net</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>771248</elocation-id>
<history>
<date date-type="received">
<day>06</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Hu, Zhang, Wang, Gao, Ong, Wang and Zheng.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Hu, Zhang, Wang, Gao, Ong, Wang and Zheng</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>CRISPR/Cas9 nucleases hold great potential for gene therapy, but they frequently induce unwanted off-target cleavage. We previously developed a GFP activation assay for detection of DNA cleavage in cells. Here, we demonstrate two novel applications of this assay. First, we use this assay to confirm off-target cleavage that cannot be detected by targeted deep sequencing in cells before. Second, we use this approach to detect multiple alternative PAMs recognized by SpCas9. These noncanonical PAMs are associated with low cleavage activity, but targets associated with these PAMs must be considered as potential off-target sites. Taken together, the GFP activation assay is a powerful platform for DNA cleavage detection in&#x20;cells.</p>
</abstract>
<kwd-group>
<kwd>CRISPR</kwd>
<kwd>genome editing</kwd>
<kwd>DNA cleavage</kwd>
<kwd>off-target</kwd>
<kwd>PAM</kwd>
</kwd-group>
<contract-num rid="cn001">82070258 81870199</contract-num>
<contract-num rid="cn002">31521003</contract-num>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Foundation for Innovative Research Groups of the National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100012659</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The RNA-guided CRISPR/Cas9 system can introduce desired mutations into the genome and therefore has a broad range of research and medical applications (<xref ref-type="bibr" rid="B2">Cong et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B11">Hwang et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B18">Mali et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B32">Xie et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B27">Wang et&#x20;al., 2019a</xref>). This system consists of a Cas9 nuclease and a guide RNA (gRNA), which forms a Cas9-gRNA complex, recognizing a target sequence (protospacer) with a downstream protospacer adjacent motif (PAM), and induces a site-specific double-strand break (DSB) (<xref ref-type="bibr" rid="B13">Jinek et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B2">Cong et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B18">Mali et&#x20;al., 2013</xref>). DSBs are repaired by either non-homologous end joining (NHEJ) or homologous recombination (HR) repair pathway, resulting in desired mutations (<xref ref-type="bibr" rid="B31">Wang et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B21">Ran et&#x20;al., 2013a</xref>; <xref ref-type="bibr" rid="B30">Wang et&#x20;al., 2014</xref>). Although the targeting specificity of Cas9 nucleases is controlled by the 20-nt guide sequence of the gRNA and the presence of a PAM adjacent to the target sequence in the genome, potential off-target cleavage could still occur (<xref ref-type="bibr" rid="B7">Fu et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B9">Hsu et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B22">Ran et&#x20;al., 2013b</xref>; <xref ref-type="bibr" rid="B8">Fu et&#x20;al., 2014</xref>). Off-target cleavage requires a DNA sequence with certain degrees of homology to the target sequence, followed by a PAM or a noncanonical PAM (<xref ref-type="bibr" rid="B9">Hsu et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B17">Lin et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B27">Wang et&#x20;al., 2019a</xref>). Off-target mutations can confound interpretation of the experiments and can have implications for the development of therapeutic applications.</p>
<p>The importance of the off-target issue has spurred the development of multiple approaches to identify the frequencies and locations of unintended off-target mutations (<xref ref-type="bibr" rid="B24">Tsai and Joung, 2016</xref>). The initial approaches are <italic>in silico</italic> prediction of potential off-target cleavage sites based on similarity to the intended target site followed by the targeted experimental assessment of indel mutations at those locations (<xref ref-type="bibr" rid="B7">Fu et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B9">Hsu et&#x20;al., 2013</xref>). Subsequently, several genome-wide unbiased approaches have been developed, including cell-based approaches (such as GUIDE-seq and HTGTS) (<xref ref-type="bibr" rid="B4">Crosetto et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B6">Frock et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B26">Tsai et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B29">Wang et&#x20;al., 2015</xref>) and cell-free approaches (such as CIRCLE-seq) (<xref ref-type="bibr" rid="B14">Kim et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B25">Tsai et&#x20;al., 2017</xref>). CIRCLE-seq is supposed to be the most sensitive approach, enabling the identification of rare off-target cleavage events <italic>in&#x20;vitro</italic> (<xref ref-type="bibr" rid="B25">Tsai et&#x20;al., 2017</xref>). However, it is a challenge to test whether the rare off-target cleavage events occur in cells. Targeted amplicon sequencing is routinely used to validate off-target mutations, but the error rate of next-generation sequencing places a floor for indel mutation detection of &#x223c;0.1% (<xref ref-type="bibr" rid="B25">Tsai et&#x20;al., 2017</xref>). Therefore, easy and sensitive approaches for DNA cleavage detection in cells are missing.</p>
<p>Previously, we developed a GFP activation assay for CRISPR PAM screening (<xref ref-type="bibr" rid="B10">Hu et&#x20;al., 2020</xref>). In this approach, a target sequence is inserted between ATG and GFP coding sequence, disrupting GFP expression. If Cas9 nucleases cleave the target sequence and induce in-frame mutations, GFP expression will be restored. In this study, we test whether this approach can be used to detect off-target cleavage. We first demonstrate that this approach enables us to verify rare off-target cleavage events that could not be detected in cells before. Next, we demonstrate that this approach enables the detection of multiple alternative SpCas9 PAMs associated with very low cleavage activity. Therefore, this GFP activation assay is a sensitive platform for DNA cleavage detection in&#x20;cells.</p>
</sec>
<sec sec-type="results" id="s2">
<title>Results</title>
<sec id="s2-1">
<title>The GFP Activation Assay for Validation of Off-Targets</title>
<p>To establish a highly sensitive approach for rare off-target cleavage detection in cells, a previous GFP activation assay was used (<xref ref-type="bibr" rid="B10">Hu et&#x20;al., 2020</xref>). A target sequence (protospacer) with a PAM is inserted between ATG start codon and GFP coding sequence, disrupting GFP expression by frameshift mutation. When Cas9 nucleases cleave the protospacer and generate small insertions/deletions (indels), a portion of cells will restore the GFP reading frame, leading to GFP expression (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>). The reporter system was delivered into HEK293T&#x20;cells by lentiviral infection to generate a stable cell line. Background GFP-positive cells caused by plasmid mutations were removed by cell sorting (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>A GFP activation assay for DNA cleavage detection. <bold>(A)</bold> Schematic diagram of the GFP activation assay. A lentiviral vector contains a CMV-driven GFP. A protospacer followed by a PAM is inserted between ATG and GFP coding sequence, disrupting GFP expression. An example of off-target sequence as well as on-target gRNA is shown below. <bold>(B)</bold> The vector is stably integrated into HEK293T&#x20;cells. Background GFP-positive cells are removed by cell sorting. After genome editing, a portion of cells will restore GFP expression. GFP-positive cells are sorted out and PAM sequences were PCR-amplified for deep-sequencing analysis. <bold>(C)</bold> Six off-target sites (for a gRNA targeting <italic>EMX1</italic>) identified by CIRCLE-seq are selected for validation in cells by the GFP activation assay. <bold>(D)</bold> Six off-target sites (for a gRNA targeting <italic>VEGFA</italic> site 1) identified by CIRCLE-seq are selected for validation in cells by the GFP activation assay. <bold>(E)</bold> Indel sequences are detected by deep sequencing for EMX1-OT5. On target sequence is shown above. Mismatches in the off-target sequence (EMX1-OT5) are shown in blue. The insertions are shown in red. The GFP sequence is shown in green. PAM is underlined.</p>
</caption>
<graphic xlink:href="fcell-09-771248-g001.tif"/>
</fig>
<p>CIRCLE-seq is the most sensitive approach for genome-wide off-target detection to date (<xref ref-type="bibr" rid="B25">Tsai et&#x20;al., 2017</xref>). Tsai et&#x20;al. identified up to hundreds of off-target sites for a given target by CIRCLE-seq, but they failed to validate a list of off-target sites in cells by using targeted amplicon sequencing (<xref ref-type="bibr" rid="B25">Tsai et&#x20;al., 2017</xref>). It possible that off-target cleavage occurred at these sites but the detection assay was not sensitive enough. To test the power of the GFP activation assay, we first chose two off-target sites (EMX1-OT5 and VEGFA-OT7; <xref ref-type="table" rid="T1">Table&#x20;1</xref>) that can be detected by both CIRCLE-seq and GUIDE-seq (<xref ref-type="bibr" rid="B25">Tsai et&#x20;al., 2017</xref>). GFP-positive cells were observed 2&#xa0;days after the transfection of SpCas9 with on-target gRNA but not SpCas9 alone (<xref ref-type="fig" rid="F1">Figures 1C,D</xref>; <xref ref-type="sec" rid="s10">Supplementary Figures S1a,S1b</xref>). The GFP-positive cells were sorted out, and the protospacer sequences were PCR-amplified for deep sequencing. Deep sequencing analysis revealed that indels occurred (<xref ref-type="fig" rid="F1">Figure&#x20;1E</xref>). These data demonstrated that the GFP activation assay enabled off-target cleavage detection in&#x20;cells.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Off-target sites of <italic>EMX1</italic> and <italic>VEGFA</italic> site 1 in this&#x20;study.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Sites</th>
<th align="center">Sequence<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref>
</th>
<th align="center">Locus</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">EMX1-On</td>
<td align="left">GAG&#x200b;TCC&#x200b;GAG&#x200b;CAG&#x200b;AAG&#x200b;AAG&#x200b;AAG&#x200b;GG</td>
<td align="center">chr2:72933853&#x2013;72933875</td>
</tr>
<tr>
<td align="left">EMX1-OT5</td>
<td align="left">AAG&#x200b;TCC&#x200b;GAG&#x200b;GAG&#x200b;AGG&#x200b;AAG&#x200b;AAA&#x200b;GG</td>
<td align="center">chr1:23384119&#x2013;23394141</td>
</tr>
<tr>
<td align="left">EMX1-OT9</td>
<td align="left">GAG&#x200b;TAC&#x200b;AAG&#x200b;CAG&#x200b;ATG&#x200b;AAA&#x200b;AAC&#x200b;GG</td>
<td align="center">chr10:126391610&#x2013;126391632</td>
</tr>
<tr>
<td align="left">EMX1-OT13</td>
<td align="left">GAG&#x200b;GCC&#x200b;AAG&#x200b;CAG&#x200b;AAA&#x200b;GAA&#x200b;AAA&#x200b;GG</td>
<td align="center">chr7:31861458&#x2013;31861480</td>
</tr>
<tr>
<td align="left">EMX1-OT31</td>
<td align="left">GAC&#x200b;TCC&#x200b;GAG&#x200b;CAG&#x200b;CAG&#x200b;AAG&#x200b;GAT&#x200b;GG</td>
<td align="center">chr2:65555376&#x2013;65555398</td>
</tr>
<tr>
<td align="left">EMX1-OT36</td>
<td align="left">GAG&#x200b;TTA&#x200b;GAG&#x200b;CAG&#x200b;AGG&#x200b;AAG&#x200b;AGA&#x200b;GG</td>
<td align="center">chr6:99251280&#x2013;99251302</td>
</tr>
<tr>
<td align="left">EMX1-OT52</td>
<td align="left">GTG&#x200b;TCA&#x200b;GAG&#x200b;CAG&#x200b;AAA&#x200b;AAG&#x200b;AGT&#x200b;GG</td>
<td align="center">chr4:25059119&#x2013;25059141</td>
</tr>
<tr>
<td align="left">VEGFA-On</td>
<td align="left">GGG&#x200b;TGG&#x200b;GGG&#x200b;GAG&#x200b;TTT&#x200b;GCT&#x200b;CCT&#x200b;GG</td>
<td align="center">chr6:43769554&#x2013;43769576</td>
</tr>
<tr>
<td align="left">VEGFA-OT5</td>
<td align="left">GGG&#x200b;GGC&#x200b;AGG&#x200b;GAG&#x200b;ATT&#x200b;GCT&#x200b;CCT&#x200b;GG</td>
<td align="center">chr18:366708&#x2013;366730</td>
</tr>
<tr>
<td align="left">VEGFA-OT7</td>
<td align="left">AAG&#x200b;TAA&#x200b;GGG&#x200b;AAG&#x200b;TTT&#x200b;GCT&#x200b;CCT&#x200b;GG</td>
<td align="center">chr16:869350&#x2013;869372</td>
</tr>
<tr>
<td align="left">VEGFA-OT19</td>
<td align="left">GGG&#x200b;AGG&#x200b;AGA&#x200b;GAG&#x200b;TTT&#x200b;GCT&#x200b;CTC&#x200b;TG</td>
<td align="center">chr8:139702078&#x2013;139702100</td>
</tr>
<tr>
<td align="left">VEGFA-OT33</td>
<td align="left">AGA&#x200b;GGG&#x200b;GTG&#x200b;GAG&#x200b;TTT&#x200b;GTT&#x200b;CCA&#x200b;GG</td>
<td align="center">chr20:38342497&#x2013;38342519</td>
</tr>
<tr>
<td align="left">VEGFA-OT49</td>
<td align="left">GGG&#x200b;GAG&#x200b;GGG&#x200b;GAG&#x200b;ATG&#x200b;GCT&#x200b;CCC&#x200b;GG</td>
<td align="center">chr10:113530631&#x2013;113530653</td>
</tr>
<tr>
<td align="left">VEGFA-OT60</td>
<td align="left">GAG&#x200b;GTG&#x200b;GGG&#x200b;TGA&#x200b;TTT&#x200b;GCT&#x200b;CCA&#x200b;GG</td>
<td align="center">chr11:57067754&#x2013;57067776</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>a</label>
<p>PAM sequences were shown in green and mismatched nucleotides were shown in&#x20;red.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We chose 10 additional off-target sites (five for <italic>EMX1</italic> and five for <italic>VEGFA</italic> site 1; <xref ref-type="table" rid="T1">Table&#x20;1</xref>) that were detected by CIRCLE-seq but failed to be validated by targeted amplicon sequencing (<xref ref-type="bibr" rid="B25">Tsai et&#x20;al., 2017</xref>). GFP-positive cells were observed for all of the tested sites 2&#xa0;days after the transfection of SpCas9 with on-target gRNA but not SpCas9 alone (<xref ref-type="fig" rid="F1">Figures 1C,D</xref>; <xref ref-type="sec" rid="s10">Supplementary Figures S1a,S1b</xref>), indicating that off-target mutations could occur with these sites in cells. Indels were confirmed by deep sequencing (<xref ref-type="sec" rid="s10">Supplementary Figures S2, S3</xref>). These data demonstrated that the GFP activation assay was a highly sensitive platform for DNA cleavage detection.</p>
</sec>
<sec id="s2-2">
<title>The GFP Activation Assay for Detection of New Non-Canonical PAMs of SpCas9</title>
<p>In addition to NGG PAM, SpCas9 also recognizes noncanonical PAMs, including NAG, NCG, NGA, and NNGG (<xref ref-type="bibr" rid="B12">Jiang et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B5">Doench et&#x20;al., 2016</xref>). We investigate whether the GFP activation assay is sensitive enough to identify additional PAMs. For this purpose, a protospacer containing 7nt downstream randomized DNA sequences was inserted between ATG start codon and GFP coding sequence, disrupting GFP expression (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>). The GFP reporter construct was stably inserted into the genome. Quantitative PCR (qPCR) revealed that there were average 3.82 copies of construct per cells. GFP-positive cells could be observed 2&#xa0;days after the transfection of SpCas9 with the corresponding gRNA but not SpCas9 alone (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>). The GFP-positive cells were sorted out, and the protospacer with randomized DNA sequences were PCR-amplified for deep sequencing. Deep sequencing analysis revealed that indels associated with different PAMs could be detected (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>A GFP activation assay for PAM screening. <bold>(A)</bold> Schematic diagram of the GFP activation assay. A lentiviral vector contains a CMV-driven GFP. A target sequence followed by a 7-bp random sequence is inserted between ATG and GFP coding sequence, disrupting GFP expression. The library is stably integrated into HEK293T&#x20;cells. After genome editing, a portion of cells will restore GFP expression. GFP-positive cells are sorted out and PAM sequences were PCR-amplified for deep-sequencing analysis. <bold>(B)</bold> Transfection of <italic>Sp</italic>Cas9 and gRNA results in GFP expression, while transfection of <italic>Sp</italic>Cas9 alone cannot induce GFP expression. <bold>(C)</bold> Deep-sequencing reveals that targets with multiple PAMs can be edited. GFP sequence is shown in green; insertion mutations are shown in red; 7-bp random sequences are a highlight in yellow.</p>
</caption>
<graphic xlink:href="fcell-09-771248-g002.tif"/>
</fig>
<p>Next, we systematically analyzed the PAM sequences recognized by SpCas9 from deep sequencing data. Only in-frame mutations were considered as novel mutations induced by SpCas9, thus minimizing the background mutations derived from library construction or deep sequencing. Since indels could disrupt the randomized DNA sequences, GCG triple-nucleotide was used to fix the 7nt randomized DNA sequences (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>). Both WebLogo and PAM wheel captured the canonical NGG as the most enriched PAM, but the sequences other than NGG were also observed (<xref ref-type="fig" rid="F3">Figures 3A,B</xref>). The nucleotide preference at position 1&#x2013;4 was not random. We analyzed the PAM frequencies for all possible NNNN PAM sequences (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>). The top 74 PAMs (frequency over 0.1%) included all NNGG, NAGN, NGAN, and GGYN PAMs (<xref ref-type="sec" rid="s10">Supplementary Figure S4</xref>). The most efficient PAM was NGGN, as expected, followed by NNGG, NAGN, NGAN, and GGYN (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>). Interestingly, some noncanonical PAMs such as GTGG, GCGG, and GAGT displayed comparable efficiency to NGGN&#x20;PAMs.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>PAM sequence analysis. <bold>(A)</bold> WebLogo is generated based on the PAM screening assay. The upper panel is the control cells without genome editing. the lower panel is the cells after genome editing. <bold>(B)</bold> PAM wheel is generated based on the PAM screening assay. <bold>(C)</bold> Heat map for efficiency ratio of top all 256 PAMs. The 1&#x2013;2 PAM sequences are shown on the left, and the 3&#x2013;4 PAM sequences are shown on the&#x20;top.</p>
</caption>
<graphic xlink:href="fcell-09-771248-g003.tif"/>
</fig>
<p>To confirm novel PAMs identified here, we isolated four GFP reporter constructs with different PAM sequences (CGCT, TGCT, GACT, and TGTA) from the PAM library and established stable cell lines for each construct (<xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>). Transfection of SpCas9 with gRNA induced GFP expression for all of them, indicating that cleavage occurred with these PAMs (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>). We also isolated a construct with GTTA PAM as a negative control. Consistent with the PAM screening results, GFP-positive cells could not be observed with GTTA PAM (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>). We further tested 21 endogenous targets with noncanonical PAMs. Two NNGG PAMs displayed very high activity, with indel rates of 64.3 and 57.6% for GCGG and CTGG, respectively (<xref ref-type="fig" rid="F4">Figure&#x20;4C</xref>). Three GGYN PAMs (GGCG, GGCT, and GGTC) as well as GTGA and GTGT PAMs also displayed significant activity. Other PAMs only displayed minimal activity. These novel PAMs are useful for <italic>in silico</italic> prediction of potential off-target&#x20;sites.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Validation of noncanonical PAMs. <bold>(A)</bold> Schematic diagram of the GFP activation assay with five targets shown below. <bold>(B)</bold> Five GFP reporter constructs with noncanonical PAMs are isolated from the PAM library and tested for genome editing. Quantification is shown on the bottom right. <italic>n</italic>&#x20;&#x3d; 3. <bold>(C)</bold> Indel frequency of endogenous target sequences associated with noncanonical PAMs. <italic>n</italic>&#x20;&#x3d; 3.</p>
</caption>
<graphic xlink:href="fcell-09-771248-g004.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s3">
<title>Discussion</title>
<p>In this study, we demonstrate that the GFP activation assay is a highly sensitive platform for DNA cleavage detection in cells. Targeted amplicon sequencing is routinely used to detect DNA cleavage, but the error rate of next-generation sequencing places a floor for indel mutation detection of &#x223c;0.1% (<xref ref-type="bibr" rid="B25">Tsai et&#x20;al., 2017</xref>). Our GFP activation assay requires a cell sorting step to enrich the cleavage events before targeted amplicon sequencing, which increases the sensitivity. GFP-disruption assay can be used for detection of DNA cleavage (<xref ref-type="bibr" rid="B20">Permyakova et&#x20;al., 2019</xref>), but it cannot detect the rare cleavage events due to the background of GFP-negative cells. In addition, GFP-disruption assay does not allow us to test non-GFP DNA sequence. &#x201c;Traffic light&#x201d; system is an elegant design for detection of DNA cleavage in cells (<xref ref-type="bibr" rid="B1">Certo et&#x20;al., 2011</xref>). This system contains a GFP cassette disrupted by a target sequence and an RFP cassette which is out of frame. If DNA cleavage occurs and DSB is repaired by NHEJ, the RFP expression will be activated. The sensitivity of this system should be comparable to our&#x20;assay.</p>
<p>In the GFP activation assay, the GFP reporter construct is inserted into the genome by lentiviruses, which preferentially integrate into transcriptionally active regions (<xref ref-type="bibr" rid="B23">Schr&#xf6;der et&#x20;al., 2002</xref>; <xref ref-type="bibr" rid="B19">Mitchell et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B15">Kim et&#x20;al., 2017</xref>). These regions are much more accessible for the CRISPR/Cas9 machinery. One limitation of this assay is that it may not reflect the real situation in the therapeutically relevant cells, where endogenous off-target sites may be not accessible for Cas9 nucleases. On the other hand, GFP activation assay has an advantage over detection at endogenous loci. When Cas9&#x2b;gRNA are delivered into the human body by adeno-associated virus (AAV) (<xref ref-type="bibr" rid="B28">Wang et&#x20;al., 2019b</xref>), AAV can also infect therapeutically irrelevant cell types, where the off-target sites may be open. It is not safe enough to only consider therapeutically relevant&#x20;cells.</p>
<p>The GFP activation assay requires to clone every potential off-target site into the vector and establishes stable cell lines, which is time-consuming. For clinical use with CRISPR/Cas9, it deserves to test very rare cleavage events happened at off-targets. It is also possible to synthesize all potential off-targets with microarray and clone them into the vector to establish a library. The library is stably integrated into chromosome. Transfection of Cas9&#x2b;gRNA can induce GFP expression. GFP-positive cells are sorted out and synthesized off-targets are PCR-amplified for deep sequencing. This procedure may allow high-throughput test of potential off-targets with GFP activation&#x20;assay.</p>
<p>SpCas9 is the most extensively studied and applied system to date due to its high efficiency and simple PAM requirement (<xref ref-type="bibr" rid="B2">Cong et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B18">Mali et&#x20;al., 2013</xref>). In addition to NGG PAM, several noncanonical PAMs including NAG, NCG, NGA, and NNGG have been identified (<xref ref-type="bibr" rid="B12">Jiang et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B5">Doench et&#x20;al., 2016</xref>). These noncanonical PAMs are associated with low cleavage activity, but targets associated with them must be considered as potential off-target sites. Therefore, it is crucial to identify additional noncanonical PAMs for SpCas9. The GFP activation assay enables to identify multiple noncanonical PAMs, dramatically extending the list of noncanonical SpCas9 PAMs. We anticipate that the GFP activation assay is also useful for other applications that require highly sensitive DNA cleavage detection, such as the test of new genome&#x20;tools.</p>
</sec>
<sec sec-type="methods" id="s4">
<title>Methods</title>
<sec id="s4-1">
<title>Cell Culture and Transfection</title>
<p>HEK293T&#x20;cells were maintained in Dulbecco&#x2019;s Modified Eagle Medium (DMEM) supplemented with 10% FBS (Gibco) and 1% antibiotics at 37&#xb0;C with 5% CO<sub>2</sub>. For the PAM library screen, HEK293T&#x20;cells were plated into 10&#xa0;cm dishes, and transfected at &#x223c;60% confluency with Cas9-gRNA-expressing plasmid (15&#xa0;&#x3bc;g) using Lipofectamine 2000 (Life Technologies). For PAM validation at endogenous sites, HEK293T&#x20;cells were seeded on 48-well plates and transfected with Cas9-gRNA-expressing plasmid (500&#xa0;ng) using Lipofectamine 2000 (Life Technologies).</p>
</sec>
<sec id="s4-2">
<title>The PAM Library Construction</title>
<p>The DNA oligonucleotides containing a target sequence followed by random sequences and flanking homologous sequences (for Gibson Assembly) were synthesized from GENEWIZ (Suzhou, China). Full-length oligonucleotides were PCR-amplified using Q5&#x20;High-Fidelity 2X Master Mix (NEB), size-selected using a 3% agarose gel EX (Life Technologies, Qiagen), and purified using MinElute Gel Extraction Kit (Qiagen). PCR products were cloned into a lentiviral vector by Gibson Assembly (NEB) and purified with Agencourt AMPure XP SPRI beads (Beckman Coulter). The Gibson Assembly products were electroporated into MegaX DH10B<sup>&#x2122;</sup> T1<sup>R</sup> Electrocomp<sup>&#x2122;</sup> Cells (Invitrogen) using a GenePulser (BioRad). The bacteria were added into recovery media and grew at 32&#xb0;C, 225&#xa0;rpm for 14&#xa0;h. The plasmid DNA was extracted from bacteria using Endotoxin-Free Plasmid Maxiprep (Qiagen). The plasmid sequence is shown in <xref ref-type="sec" rid="s10">Supplementary Figure S5</xref>. All primers and gRNA sequences used in this study were listed in <xref ref-type="sec" rid="s10">Supplementary Table&#x20;S1</xref>.</p>
</sec>
<sec id="s4-3">
<title>Lentivirus Production</title>
<p>For PAM library packaging, HEK293T&#x20;cells were seeded in three 10&#xa0;cm dishes and transfected at &#x223c;40% confluency. For each dish, 12&#xa0;&#x3bc;g of PAM library plasmid, 9&#xa0;&#x3bc;g of psPAX2, and 3&#xa0;&#x3bc;g of pMD2.G were transfected with 60&#xa0;&#x3bc;L of Lipofectamine 2000 (Life Technologies). Viruses were harvested twice at 48 and 72&#xa0;h post-transfection. The viruses were concentrated using PEG8000 (no. LV810A-1, SBI, Palo Alto, CA), dissolved in PBS and stored at &#x2212;80&#xb0;C. For single PAM reporter construct packaging, HEK293T&#x20;cells were seeded into 6-well plates, 1.2&#xa0;&#x3bc;g of PAM reporter plasmid, 0.9&#xa0;&#x3bc;g of psPAX2, and 0.3&#xa0;&#x3bc;g of pMD2.G were transfected with 5&#xa0;&#x3bc;L of Lipofectamine 2000. Viruses were harvested twice at 48 and 72&#xa0;h post-transfection.</p>
</sec>
<sec id="s4-4">
<title>PAM Library Screening Assay</title>
<p>HEK293T&#x20;cells were plated into a 15&#xa0;cm dish at &#x223c;30% confluence. After 24&#xa0;h, cells were infected with PAM library lentiviruses with at least 1000-fold coverage of each PAM. 24&#xa0;h after infection, the cells were selected with 2&#xa0;&#xb5;g/ml of puromycin for 5&#xa0;days. To remove plasmid mutations that induce GFP expression, the GFP negative cells were sorted out with a MoFlo XDP machine (Beckman Coulter) and seeded into 10&#xa0;cm dishes. The residual GFP-positive cells were removed pipette tips under microscope. For the PAM screen, PAM library cells were transfected with Cas9-gRNA expressing plasmid for 3&#xa0;days. The GFP-positive cells were sorted out by MoFlo XDP machine and the genomic DNA was isolated using TIANamp Genomic DNA Kit (TIANGEN) following the manufacturer&#x2019;s instructions. DNA target sites were PCR-amplified by nested PCR with Q5&#x20;High-Fidelity 2X Master Mix (NEB). First, the target region was PCR-amplified using primers Deep-F1/R1 with 25 cycles; second, 3&#xa0;&#x3bc;L of PCR products from the first step were used as a template and amplified by primers P5-adapter-F and P7-adapter-R for 15 cycles. The PCR products were purified using the Gel Extraction Kit (Qiagen) and sequenced on Illumina HiSeq X by 150-bp paired-end sequencing.</p>
</sec>
<sec id="s4-5">
<title>PAM Sequence Analysis</title>
<p>Twenty base-pair sequences (AAG&#x200b;CCT&#x200b;TGT&#x200b;TTG&#x200b;CCA&#x200b;CCA&#x200b;TG/GTG&#x200b;AGC&#x200b;AAG&#x200b;GGC&#x200b;GAG&#x200b;GAG&#x200b;CT) flanking the target sequence (GAACGGCTCGGAGATCATCATTGCGNNNNNNN) were used to fix the target sequence. Only target sequences with in-frame mutations were used for PAM analysis. GCG and GTG&#x200b;AGC&#x200b;AAG&#x200b;GGC&#x200b;GAG&#x200b;GAG&#x200b;CT sequences were used to fix a 7-bp random sequence. Only intact 7-bp random sequences were used for PAM analysis. The 7-bp random sequences were extracted and visualized by WebLog3 (<xref ref-type="bibr" rid="B3">Crooks et al., 2004</xref>) and wheel chart (<xref ref-type="bibr" rid="B16">Leenay et al., 2016</xref>) to demonstrate&#x20;PAMs.</p>
</sec>
<sec id="s4-6">
<title>Plasmid Constructs and DNA Cleavage Detection</title>
<p>Plasmids containing specific PAM sequences were isolated from the PAM library. Plasmids of EMX1-OT and VEGFA-OT construction: vector backbone of the plasmid containing specific PAM sequences was PCR-amplified using primers EMX1/VEGFA-OT-F/cozak-R, followed by phosphorylation with T4 Polynucleotide Kinase (NEB) and religation with T4 DNA ligase (NEB). Each plasmid was packed into lentiviruses to generate a stable cell line. To remove plasmid mutations that induce GFP expression, the GFP-negative cells were sorted out by the MoFlo XDP machine (Beckman Coulter). The cells were seeded into 24-well and transfected with 800&#xa0;ng of SpCas9-gRNA-expressing plasmid (PX459, addgene &#x23;118632) by Lipofectamine 2000 (Life Technologies). Five days after transfection, the GFP-positive cells were measured on the Calibur instrument (BD). Data were analyzed using FlowJo. Besides, GFP-positive cells of EMX1-OT, and VEGFA-OT were sorted out by the MoFlo XDP machine (Beckman Coulter). The genomic DNA was isolated and target sites were amplified by nested PCR and extracted by Gel Extraction Kit (QIAGEN). The amplicons are prepared for deep sequencing.</p>
</sec>
<sec id="s4-7">
<title>Test of PAM Activity at Endogenous Sites</title>
<p>HEK293T&#x20;cells were seeded on 24-well plates and transfected with epiCRISPR(4) constructs expressing SpCas9 and gRNA followed by puromycin selection (2&#xa0;&#xb5;g/ml) for 6&#xa0;days. The genomic DNA was isolated, and the target sites were PCR-amplified by nested PCR for deep sequencing.</p>
</sec>
<sec id="s4-8">
<title>Quantification of GFP Reporter Copy Number</title>
<p>The genomic DNA was isolated from GFP activation cells using TIANamp Genomic DNA Kit (TIANGEN) following the manufacturer&#x2019;s instructions. To generate standard curve, GFP reporter plasmid was serially diluted to final concentrations of 10<sup>9</sup>,10<sup>8</sup>,10<sup>7</sup>,10<sup>6</sup>,10<sup>5</sup>,10<sup>4</sup>,10<sup>3</sup>,10<sup>2</sup> copies/&#x3bc;L. Quantitative PCR were performed with CFX Connect Real-Time System (Bio-Rad) and 2X SYBR Green qPCR Master Mix (APExBIO). Use the following parameters: 1 cycle at 95&#xb0;C for 2&#xa0;min, followed by 40 cycles of 95&#xb0;C for 15&#xa0;s, 55&#xb0;C for 30&#xa0;s, and 72&#xb0;C for 30&#xa0;s. Each sample was quantified in triplicate. The same parameters were used to quantify GFP copy numbers in the genomic DNA. Absolute transgene copy numbers were calculated with C<sub>q</sub> values and dilution factor based on standard&#x20;curve.</p>
</sec>
<sec id="s4-9">
<title>Quantification and Statistical Analysis</title>
<p>All the data are shown as the mean&#x20;&#xb1; S.D. Statistical analyses were conducted using Microsoft Excel.</p>
</sec>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The data presented in this study are deposited in the NCBI SRA BioProject repository, accession number is PRJNA773240.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>ZH, DW, and SG: performed the experiments; CZ: analyzed the data; SO: edited the writing; YW: designed the experiments and wrote the article; WZ: supervised the project and offered grant support. All authors read and approved the final article.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work was supported by grants from the National Natural Science Foundation of China (82070258, 81870199), the Foundation for Innovative Research Group of the National Natural Science Foundation of China (31521003), Science and Technology Research Program of Shanghai (19DZ2282100), Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University (No. SKLGE-2104), the Scientific Research Foundation of Peking University Shenzhen Hospital KYQD202100X.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcell.2021.771248/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcell.2021.771248/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM1" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Certo</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>B. Y.</given-names>
</name>
<name>
<surname>Annis</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Garibov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jarjour</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rawlings</surname>
<given-names>D. J.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Tracking Genome Engineering Outcome at Individual DNA Breakpoints</article-title>. <source>Nat. Methods</source> <volume>8</volume>, <fpage>671</fpage>&#x2013;<lpage>676</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1648</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barretto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Habib</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Multiplex Genome Engineering Using CRISPR/Cas Systems</article-title>. <source>Science</source> <volume>339</volume>, <fpage>819</fpage>&#x2013;<lpage>823</lpage>. <pub-id pub-id-type="doi">10.1126/science.1231143</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crooks</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Hon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chandonia</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>S. E.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>WebLogo: A Sequence Logo Generator</article-title>. <source>Genome Res.</source> <volume>14</volume>, <fpage>1188</fpage>&#x2013;<lpage>1190</lpage>. <pub-id pub-id-type="doi">10.1101/gr.849004</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crosetto</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Bienko</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dojer</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Nucleotide-resolution DNA Double-Strand Break Mapping by Next-Generation Sequencing</article-title>. <source>Nat. Methods</source> <volume>10</volume>, <fpage>361</fpage>&#x2013;<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2408</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doench</surname>
<given-names>J.&#x20;G.</given-names>
</name>
<name>
<surname>Fusi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sullender</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vaimberg</surname>
<given-names>E. W.</given-names>
</name>
<name>
<surname>Donovan</surname>
<given-names>K. F.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Optimized sgRNA Design to Maximize Activity and Minimize Off-Target Effects of CRISPR-Cas9</article-title>. <source>Nat. Biotechnol.</source> <volume>34</volume>, <fpage>184</fpage>&#x2013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3437</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frock</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meyers</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>Y.-J.</given-names>
</name>
<name>
<surname>Kii</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alt</surname>
<given-names>F. W.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Genome-wide Detection of DNA Double-Stranded Breaks Induced by Engineered Nucleases</article-title>. <source>Nat. Biotechnol.</source> <volume>33</volume>, <fpage>179</fpage>&#x2013;<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3101</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Foden</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Khayter</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Maeder</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Reyon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>J.&#x20;K.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>High-frequency Off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells</article-title>. <source>Nat. Biotechnol.</source> <volume>31</volume>, <fpage>822</fpage>&#x2013;<lpage>826</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2623</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Reyon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cascio</surname>
<given-names>V. M.</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>J.&#x20;K.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Improving CRISPR-Cas Nuclease Specificity Using Truncated Guide RNAs</article-title>. <source>Nat. Biotechnol.</source> <volume>32</volume>, <fpage>279</fpage>&#x2013;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2808</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Weinstein</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Konermann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Agarwala</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>DNA Targeting Specificity of RNA-Guided Cas9 Nucleases</article-title>. <source>Nat. Biotechnol.</source> <volume>31</volume>, <fpage>827</fpage>&#x2013;<lpage>832</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2647</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Compact Cas9 Ortholog from Staphylococcus Auricularis (SauriCas9) Expands the DNA Targeting Scope</article-title>. <source>Plos Biol.</source> <volume>18</volume>, <fpage>e3000686</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.3000686</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>W. Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Reyon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Maeder</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>S. Q.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Efficient Genome Editing in Zebrafish Using a CRISPR-Cas System</article-title>. <source>Nat. Biotechnol.</source> <volume>31</volume>, <fpage>227</fpage>&#x2013;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2501</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bikard</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marraffini</surname>
<given-names>L. A.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>RNA-guided Editing of Bacterial Genomes Using CRISPR-Cas Systems</article-title>. <source>Nat. Biotechnol.</source> <volume>31</volume>, <fpage>233</fpage>&#x2013;<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2508</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jinek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chylinski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fonfara</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hauer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Doudna</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Charpentier</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity</article-title>. <source>Science</source> <volume>337</volume>, <fpage>816</fpage>&#x2013;<lpage>821</lpage>. <pub-id pub-id-type="doi">10.1126/science.1225829</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H. R.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Digenome-seq: Genome-wide Profiling of CRISPR-Cas9 Off-Target Effects in Human Cells</article-title>. <source>Nat. Methods</source> <volume>12</volume> (<issue>3</issue>), <fpage>237</fpage>&#x2013;<lpage>243</lpage>. <comment>231&#x20;p following 243</comment>. <pub-id pub-id-type="doi">10.1038/nmeth.3284</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>Y.-M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>
<italic>In Vivo</italic> high-throughput Profiling of CRISPR-Cpf1 Activity</article-title>. <source>Nat. Methods</source> <volume>14</volume>, <fpage>153</fpage>&#x2013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.4104</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leenay</surname>
<given-names>R. T.</given-names>
</name>
<name>
<surname>Maksimchuk</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Slotkowski</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>R. N.</given-names>
</name>
<name>
<surname>Gomaa</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Briner</surname>
<given-names>A. E.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Identifying and Visualizing Functional PAM Diversity across CRISPR-Cas Systems</article-title>. <source>Mol. Cel.</source> <volume>62</volume>, <fpage>137</fpage>&#x2013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2016.02.031</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cradick</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Deshmukh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ranjan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sarode</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>CRISPR/Cas9 Systems Have Off-Target Activity with Insertions or Deletions between Target DNA and Guide RNA Sequences</article-title>. <source>Nucleic Acids Res.</source> <volume>42</volume>, <fpage>7473</fpage>&#x2013;<lpage>7485</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku402</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mali</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Esvelt</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Aach</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guell</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>DiCarlo</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>RNA-guided Human Genome Engineering via Cas9</article-title>. <source>Science</source> <volume>339</volume>, <fpage>823</fpage>&#x2013;<lpage>826</lpage>. <pub-id pub-id-type="doi">10.1126/science.1232033</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Beitzel</surname>
<given-names>B. F.</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Shinn</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>C. C.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences</article-title>. <source>Plos Biol.</source> <volume>2</volume>, <fpage>E234</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.0020234</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Permyakova</surname>
<given-names>N. V.</given-names>
</name>
<name>
<surname>Sidorchuk</surname>
<given-names>Y. V.</given-names>
</name>
<name>
<surname>Marenkova</surname>
<given-names>T. V.</given-names>
</name>
<name>
<surname>Khozeeva</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Kuznetsov</surname>
<given-names>V. V.</given-names>
</name>
<name>
<surname>Zagorskaya</surname>
<given-names>A. A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>CRISPR/Cas9-mediated Gfp Gene Inactivation in Arabidopsis Suspension Cells</article-title>. <source>Mol. Biol. Rep.</source> <volume>46</volume>, <fpage>5735</fpage>&#x2013;<lpage>5743</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-019-05007-y</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ran</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Gootenberg</surname>
<given-names>J.&#x20;S.</given-names>
</name>
<name>
<surname>Konermann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trevino</surname>
<given-names>A. E.</given-names>
</name>
<etal/>
</person-group> (<year>2013a</year>). <article-title>Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity</article-title>. <source>Cell</source> <volume>154</volume>, <fpage>1380</fpage>&#x2013;<lpage>1389</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.08.021</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ran</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Agarwala</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2013b</year>). <article-title>Genome Engineering Using the CRISPR-Cas9 System</article-title>. <source>Nat. Protoc.</source> <volume>8</volume>, <fpage>2281</fpage>&#x2013;<lpage>2308</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schr&#xf6;der</surname>
<given-names>A. R. W.</given-names>
</name>
<name>
<surname>Shinn</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ecker</surname>
<given-names>J.&#x20;R.</given-names>
</name>
<name>
<surname>Bushman</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots</article-title>. <source>Cell</source> <volume>110</volume>, <fpage>521</fpage>&#x2013;<lpage>529</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(02)00864-4</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>S. Q.</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>J.&#x20;K.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Defining and Improving the Genome-wide Specificities of CRISPR-Cas9 Nucleases</article-title>. <source>Nat. Rev. Genet.</source> <volume>17</volume>, <fpage>300</fpage>&#x2013;<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1038/nrg.2016.28</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>S. Q.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>N. T.</given-names>
</name>
<name>
<surname>Malagon-Lopez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Topkar</surname>
<given-names>V. V.</given-names>
</name>
<name>
<surname>Aryee</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>J.&#x20;K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>CIRCLE-seq: a Highly Sensitive <italic>In Vitro</italic> Screen for Genome-wide CRISPR-Cas9 Nuclease Off-Targets</article-title>. <source>Nat. Methods</source> <volume>14</volume>, <fpage>607</fpage>&#x2013;<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.4278</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>S. Q.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>N. T.</given-names>
</name>
<name>
<surname>Liebers</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Topkar</surname>
<given-names>V. V.</given-names>
</name>
<name>
<surname>Thapar</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>GUIDE-seq Enables Genome-wide Profiling of Off-Target Cleavage by CRISPR-Cas Nucleases</article-title>. <source>Nat. Biotechnol.</source> <volume>33</volume>, <fpage>187</fpage>&#x2013;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3117</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ong</surname>
<given-names>S.-G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019a</year>). <article-title>krCRISPR: an Easy and Efficient Strategy for Generating Conditional Knockout of Essential Genes in Cells</article-title>. <source>J.&#x20;Biol. Eng.</source> <volume>13</volume>, <fpage>35</fpage>. <pub-id pub-id-type="doi">10.1186/s13036-019-0150-y</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>P. W. L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019b</year>). <article-title>Adeno-associated Virus Vector as a Platform for Gene Therapy Delivery</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>18</volume>, <fpage>358</fpage>&#x2013;<lpage>378</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-019-0012-9</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Unbiased Detection of Off-Target Cleavage by CRISPR-Cas9 and TALENs Using Integrase-Defective Lentiviral Vectors</article-title>. <source>Nat. Biotechnol.</source> <volume>33</volume>, <fpage>175</fpage>&#x2013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3127</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lisowski</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Genome Editing of Isogenic Human Induced Pluripotent Stem Cells Recapitulates Long QT Phenotype for Drug Testing</article-title>. <source>J.&#x20;Am. Coll. Cardiol.</source> <volume>64</volume>, <fpage>451</fpage>&#x2013;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2014.04.057</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W. Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Genome Editing of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells with Zinc finger Nucleases for Cellular Imaging</article-title>. <source>Circ. Res.</source> <volume>111</volume>, <fpage>1494</fpage>&#x2013;<lpage>1503</lpage>. <pub-id pub-id-type="doi">10.1161/circresaha.112.274969</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>An Episomal Vector-Based CRISPR/Cas9 System for Highly Efficient Gene Knockout in Human Pluripotent Stem Cells</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>2320</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-02456-y</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>